These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31066093)

  • 1. A conditional error function approach for adaptive enrichment designs with continuous endpoints.
    Placzek M; Friede T
    Stat Med; 2019 Jul; 38(17):3105-3122. PubMed ID: 31066093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup.
    Sugitani T; Posch M; Bretz F; Koenig F
    Stat Med; 2018 Oct; 37(24):3387-3402. PubMed ID: 29945304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive enrichment designs with a continuous biomarker.
    Stallard N
    Biometrics; 2023 Mar; 79(1):9-19. PubMed ID: 35174875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies.
    Placzek M; Friede T
    Stat Methods Med Res; 2018 Nov; 27(11):3286-3303. PubMed ID: 29298604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point estimation following two-stage adaptive threshold enrichment clinical trials.
    Kimani PK; Todd S; Renfro LA; Stallard N
    Stat Med; 2018 Sep; 37(22):3179-3196. PubMed ID: 29855066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive graph-based multiple testing procedures.
    Klinglmueller F; Posch M; Koenig F
    Pharm Stat; 2014; 13(6):345-56. PubMed ID: 25319733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extension of adaptive alpha allocation methods for strong control of the family-wise error rate.
    Li H; Sankoh AJ; D'Agostino RB
    Stat Med; 2013 Jan; 32(2):181-95. PubMed ID: 22806685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonparametric adaptive enrichment designs using categorical surrogate data.
    Brückner M; Burger HU; Brannath W
    Stat Med; 2018 Dec; 37(29):4507-4524. PubMed ID: 30191578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An additive boundary for group sequential designs with connection to conditional error.
    Xi D; Gallo P
    Stat Med; 2019 Oct; 38(23):4656-4669. PubMed ID: 31338847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.